Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;2017:1430350.
doi: 10.1155/2017/1430350. Epub 2017 Feb 13.

Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis: Current and Future Perspectives

Affiliations
Free PMC article
Review

Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis: Current and Future Perspectives

Scott D Collum et al. Can Respir J. .
Free PMC article

Abstract

Pulmonary hypertension (PH) is commonly present in patients with chronic lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) or Idiopathic Pulmonary Fibrosis (IPF) where it is classified as Group III PH by the World Health Organization (WHO). PH has been identified to be present in as much as 40% of patients with COPD or IPF and it is considered as one of the principal predictors of mortality in patients with COPD or IPF. However, despite the prevalence and fatal consequences of PH in the setting of chronic lung diseases, there are limited therapies available for patients with Group III PH, with lung transplantation remaining as the most viable option. This highlights our need to enhance our understanding of the molecular mechanisms that lead to the development of Group III PH. In this review we have chosen to focus on the current understating of PH in IPF, we will revisit the main mediators that have been shown to play a role in the development of the disease. We will also discuss the experimental models available to study PH associated with lung fibrosis and address the role of the right ventricle in IPF. Finally we will summarize the current available treatment options for Group III PH outside of lung transplantation.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
Cellular processes and mediators involved in the pathogenesis of PH associated with lung fibrosis.

Similar articles

See all similar articles

Cited by 13 articles

See all "Cited by" articles

References

    1. CDC. National Center for Health Statistics—Leading Causes of Death, September 2016, http://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
    1. The Lancet Respiratory Medicine. Lung disease left out in the cold. The Lancet Respiratory Medicine. 2016;4(7):p. 527. doi: 10.1016/s2213-2600(16)30155-2. - DOI - PubMed
    1. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. European Respiratory Journal. 2008;32(5):1371–1385. doi: 10.1183/09031936.00015608. - DOI - PubMed
    1. Klinger J. R. Group III pulmonary hypertension: pulmonary hypertension associated with lung disease: epidemiology, pathophysiology, and treatments. Cardiology Clinics. 2016;34(3):413–433. doi: 10.1016/j.ccl.2016.04.003. - DOI - PubMed
    1. Hoeper M. M., Bogaard H. J., Condliffe R., et al. Definitions and diagnosis of pulmonary hypertension. Journal of the American College of Cardiology. 2013;62(25):D42–D50. doi: 10.1016/j.jacc.2013.10.032. - DOI - PubMed

MeSH terms

Feedback